Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Autoimmunity Highlights
Published in: Autoimmunity Highlights 2/2013

01-08-2013 | Review Article

Detection of autoantibodies in a point-of-care rheumatology setting

Authors: Konstantin N. Konstantinov, Antonios Tzamaloukas, Robert L. Rubin

Published in: Autoimmunity Highlights | Issue 2/2013

Login to get access

Abstract

Autoimmune rheumatic diseases are common and confront society with serious medical, social, and financial burdens imposed by their debilitating nature. Many autoimmune diseases are associated with a particular set of autoantibodies, which have emerged as highly useful to define and classify disease, predict flares, or monitor efficacy of therapy. However, current practice for monitoring autoantibodies is protracted, labor-intensive, and expensive. This review provides an overview on the value of point-of-care (POC) biosensor technology in the diagnosis and management of patients with autoimmune rheumatic diseases. Real-time measurement of autoantibodies will clearly benefit the rheumatology practice in emergency and urgent care settings, where definitive diagnosis is essential for initiation of correct critical care therapy. Immediate serological information in clinic will provide considerable value for long-term patient care and an opportunity for an instant, result-deduced therapeutic action, avoiding delays and improving compliance, especially in field-based and remote areas. We describe the particular autoantibodies that are useful disease and activity markers and would, therefore, be attractive to POC applications. Already existing biosensors and platforms that show promise for autoantibody testing are summarized and comparatively evaluated. As POC assessment is gaining momentum in several areas of patient care, we propose that rheumatology is poised to benefit from this innovative and affordable technology.
Literature
1.
Jacobson DL, Gange SJ, Rose NR, Graham NM et al (1997) Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 84:223–243PubMedCrossRef
2.
Yelin E, Cisternas MG, Pasta DJ, Trupin L, Murphy L, Helmick CG (2004) Medical care expenditures and earning losses of persons with arthritis and other rheumatic conditions in the United States in 1997: total and incremental estimates. Arthritis Rheum 50:2317–2326PubMedCrossRef
3.
Epstein AM, McNell BJ (1986) Relationship of beliefs and behavior in test ordering. Am J Med 80:865–870PubMedCrossRef
4.
Donald F, Waed MM (1998) Evaluative laboratory testing practices of United States rheumatologists. Arthritis Rheum 41:725–729PubMedCrossRef
5.
Janssen NM, Karnad DR, Guntupalli KK (2002) Rheumatologic diseases in intensive care unit: epidemiology, clinical approach, management, and outcome. Crit Care Clin 18:729–748PubMedCrossRef
6.
Smarma M, Lelrisalo-Repo M (1997) Arthritis patient as an emergency case at a university hospital. Scand J Rheumatol 26:30–36CrossRef
7.
8.
Ronnelid J, Huang YH, Norlander T, Rodberg S, Nilsson B, Gustafsson R et al (1994) Short-term kinetics of the humoral anti-C1q response in SLE using the ELISPOT method: fast decline in production in response to steroids. Scand J Immunol 40:243–250PubMedCrossRef
9.
Out HJ, de Groot PG, Hasselaar P, dan Vliet M, Derksen RH (1989) Fluctuations of anticardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective study. Ann Rheum Dis 48:1023–1028PubMedPubMedCentralCrossRef
10.
Rarok AA, van der Geld YM, Stegeman CA, Limburg PC, Kallenberg CG (2003) Diversity of PR3-ANCA epitope specificity in Wegener’s granulomatosis. Analysis using the biosensor technology. J Clin Immunol 23:460–468PubMedCrossRef
11.
Faust TW, Chang EH, Kowal C, Berlin R, Gazaryan IG, Bertini E et al (2010) Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc Natl Acad Sci USA 107:18569–18574PubMedPubMedCentralCrossRef
12.
Wiik AS (2010) Autoantibodies in ANCA-associated vasculitis. Rheum Dis Clin N Am 36:479–489CrossRef
13.
Kavanaugh AF, Solomon DH (2002) American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum 47:546–555PubMedCrossRef
14.
Guillermin F (2003) Assessment of disease activity. Best Practice Res Clin Rheum 17:415–426CrossRef
15.
Ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG (1990) Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. Arthritis Rheum 33:634–643PubMedCrossRef
16.
Linnik MD, Hu JZ, Heilbrunn KR, Strand V, Hurley FL, Joh T et al (2005) Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 52:1129–1137PubMedCrossRef
17.
Pan N, Amigues I, Duculan R, Aziz F, Lyman SL, Crow MK et al (2011) Rapid surges of anti-dsDNA titers predict severe clinical flares in systemic lupus erythematosus. ACR, Chicago (presentation number 1709)
18.
Ho A, Magder LS, Barr SG, Petri M (2001) Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 44:2342–2349PubMedCrossRef
19.
Suleiman S, Kamaliah D, Nadeem A, Naing NN, Maraina CHC (2009) Anti-nucleosome antibodies as a disease activity marker in patients with systemic lupus erythematosus. Int J Rheum Dis 12:100–106PubMedCrossRef
20.
Kiss E, Lakos G, Szegedi G, Poor G, Szodoray P et al (2009) Anti-nucleosome antibody, a reliable indicator for lupus nephritis. Autoimmunity 42:393–398PubMedCrossRef
21.
Ng KP, Manson JJ, Rahman A, Isenberg DA et al (2006) Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 55:900–904PubMedCrossRef
22.
Akhter E, Burlingame RW, Seaman AL, Magder L, Petri M (2011) Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus 20:1267–1274PubMedCrossRef
23.
Meyer OC, Nicaise-Roland P, Cadoudal N, Grootenboer-Mignot S, Palazzo E, Hayem G et al (2009) Anti-C1q antibodies antedate patient active glomerulonephritis in patients with systemic lupus erythematosus. Arthritis Res Ther 11:R87PubMedPubMedCentralCrossRef
24.
Moura CG, Lima I, Barbosa L, Athanazio D, Reis E, Reis M et al (2009) Anti-C1q antibodies: association with nephritis and disease activity in systemic lupus erythematosus. J Clin Lab Anal 23:19–23PubMedCrossRef
25.
Katsumata Y, Miyake K, Kawaguchi Y, Okamoto Y, Kawamoto M, Gono T et al (2011) Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis. Arthritis Rheum 63:2436–2444PubMedCrossRef
26.
Arinuma Y, Yanagida T, Hirohata S (2008) Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 58:1130–1135PubMedCrossRef
27.
Yoshio T, Onda K, Nara H, Minota S (2006) Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 54:675–681PubMedCrossRef
28.
Sjowall C, Zickert A, Skogh T, Wettero J, Gunnarsson I et al (2009) Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. Arthritis Res Ther 11:R188PubMedPubMedCentralCrossRef
29.
Morimoto AM, Flesher DT, Yang J, Wolslegel K, Wang X, Brady A et al (2011) Association of endogenous anti-interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 63:2407–2415PubMedPubMedCentralCrossRef
30.
Sanders J-SF, Huitma MG, Kallenberg CGM, Stegeman CA (2006) Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology 45:724–729PubMedCrossRef
31.
Stegeman CA (2002) Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis. Nephrol Dial Transplant 17:2077–2080PubMedCrossRef
32.
Hogan SL, Falk RJ, Chin H, Cai J, Jennette C, Jennette JC et al (2005) Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 143:621–631PubMedCrossRef
33.
Terrier B, Saadoun D, Sene D, Ghillani P, Amoura Z, Deray G et al (2009) Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides. Ann Rheum Dis 68:1564–1571PubMedCrossRef
34.
Han WK, Choi HK, Roth RM, McCluskey RT, Niles JL et al (2003) Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis. Kidney Int 63:1079–1085PubMedCrossRef
35.
Zhao J, Cui Z, Yang R, Jia X, Zhang Y, Zhao M et al (2009) Anti-glomerular basement membrane autoantibodies against different target antigens are associated with disease severity. Kidney Int 76:1108–1115PubMedCrossRef
36.
Rutgers A, Heeringa P, Damoiseaux JG, Cohen Tervaert JW et al (2003) ANCA and anti-GBM antibodies in diagnosis and follow-up of vasculitic disease. Eur J Intern Med 14:287–295PubMedCrossRef
37.
Hu PQ, Fertig N, Medsger TA Jr, Wright TM (2003) Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 48:1363–1373PubMedCrossRef
38.
Kuwana M, Kaburaki J, Mimori T, Kawakami Y, Tojo T (2000) Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 43:1074–1084PubMedCrossRef
39.
Hanke K, Dahnrich C, Bruckner CS, Huscher D, Becker M, Jansen A et al (2009) Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthritis Res Ther 11:R28PubMedPubMedCentralCrossRef
40.
Bartelds GM, Krieckaert CLM, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JWR et al (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305:1460–1468PubMedCrossRef
41.
Wilson WA, Gharavi AE, Koike T, Lockshin MD, Ware Branch D, Piette J-C et al (1999) International consensus statement on preliminary classification criteria for definitive antiphospholipid syndrome. Arthritis Rheum 42:1309–1311PubMedCrossRef
42.
Escalante A, Brey RB, Mitchell BD, Dreiner U (1995) Accuracy of anti-cardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am J Med 98:559–565PubMedCrossRef
43.
Lopez LR, Dier KJ, Lopez D, Merrill JT, Fink CA (2004) Anti-β2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol 121:142–149PubMedCrossRef
44.
Benveniste O, Drouot L, Jouen F, Charuel J-L, Bloch-Queyrat C, Behin A et al (2011) Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 63:1961–1971PubMedCrossRef
45.
Peyvandi F, Lavoretano S, Palla R, Feyes HB, Vanhoorelbeke K, Battagliolo T et al (2008) ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 93:232–239PubMedCrossRef
46.
Lammle B, Kremer Hovinga JA, George JN (2008) ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease. Haematologica 93:172–177PubMedCrossRef
47.
Jaeggi E, Laskin C, Hamilton R, Kingdom J, Silverman E (2010) The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus. J Am Coll Cardiol 55:2778–2784PubMedCrossRef
48.
Strandberg L, Winqvist o, Sonesson S-E, Mohseni S, Salomonsson S, Bremme K et al (2008) Antibodies to amino acid 200–239 (p200) of Ro52 as a serological markers for the risk of developing congenital heart block. Clin Exp Immunol 154:30–37PubMedPubMedCentralCrossRef
49.
Silverman ED, Buyon J, Laxer RM, Hamilton R, Bini P, Chu J-L et al (1995) Autoantibody response to the Ro/La particle may predict outcome in neonatal lupus erythematosus. Clin Exp Immunol 100:499–505PubMedPubMedCentralCrossRef
50.
Watanabe A, Kodera M, Siguira K, Usuda T, Tan EM, Takasaki Y et al (2004) Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum 50:892–900PubMedCrossRef
51.
Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LEC (2011) Pattern on antinuclear antibody-Hep-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 63:191–200PubMedCrossRef
52.
Gibson DS, Rooney ME, Finnegan S, Qiu J, Thomson DC, LaBaer J et al (2012) Biomarkers in rheumatology, now and in the future. Rheumatology 51:423–433PubMedCrossRef
53.
Pakkila H, Soukka T (2011) Simple and inexpensive immunoassay-based diagnostic tests. Bioanal Rev 3:27–40CrossRef
54.
55.
Choi S, Goryll M, Sin LYM, Wong PK, Chae J et al (2011) Microfluidic-based biosensors toward point-of-care detection of nucleic acid and proteins. Microfluid Nanofluid 10:231–247CrossRef
56.
von Lode P (2005) Point-of-care immunotesting: approaching the analytical performance of central laboratory methods. Clin Biochem 38:591–606CrossRef
57.
American College of Rheumatology (2005) Clinical laboratory testing position statement. American College of Rheumatology, Atlanta
58.
59.
Shoenfeld Y, Selmi C, Zimlichman E, Gershwin ME (2008) The autoimmunologist: geoepidemiology, a new center of gravity, and a prime time for autoimmunity. J Autoimmun 31:325–330PubMedCrossRef
60.
Ricci F, Adornetto G, Moscone D, Plaxco KW, Palleschi G (2010) Quantitative, reagentless, single-step electrochemical detection of anti-DNA antibodies directly in blood serum. Chem Commun 46:1742–1744CrossRef
61.
Fakhrullin RF, Vinter VG, Zamaleeva AI, Matveeva MV, Kourbanov RA, Temesgen BK et al (2007) Quartz crystal microbalance immunosensor for the detection of antibodies to double-stranded DNA. Anal Bioanal Chem 388:367–375PubMedCrossRef
62.
Buhl A, Metzger JH, Heegard NHH, Von Landenberg P, Fleck M, Luppa PB (2007) Novel biosensor-based analytic device for the detection of anti-double-stranded DNA antibodies. Clin Chem 53:334–341PubMedCrossRef
63.
Burbelo PD, Ching KH, Issa AT, Loftus CM, Li Y, Sato M et al (2009) Rapid serological detection of autoantibodies associated with Sjogren’s syndrome. J Transl Med 7:83–90PubMedPubMedCentralCrossRef
64.
Konstantinov KN, Stdikov RA, Lopez GP, Atanassov P, Rubin RL (2009) Rapid detection of anti-chromatin autoantibodies in human serum using a portable electrochemical biosensor. Biosens Bioelectron 7:1949–1954CrossRef
65.
Renger F, Bang H, Feist E, Fredenhagen G, Natusch A, Backhaus M et al (2010) Immediate determination of ACPA and rheumatoid factor—a novel point of care test for detection of anti-MCV antibodies and rheumatoid factor using a lateral-flow immunoassay. Arthritis Res Ther 12:R120PubMedPubMedCentralCrossRef
66.
Liao J, Ip W, Cheung K, Wan W, Cautherley GWH, Cai X et al (2011) Diagnostic utility of an anti-CCP point-of-care immunotest in Chinese patients with rheumatoid arthritis. Clin Chim Acta 412:778–781PubMedCrossRef
67.
Lokate AMC, Beusink JB, Besselink GAJ, Pruijn GJM, Schasfoort RBM (2007) Biomolecular interaction monitoring of autoantibodies by scanning surface plasmon resonance microarray imaging. J Am Chem Soc 129:14013–14018PubMedCrossRef
68.
Metzger J, von Landenberg P, Kehrel M, Buhl A, Lackner K, Luppa PB (2007) Biosensor analysis of β2-glycoprotein I–reactive autoantibodies: evidence for isotype-specific binding and differentiation of pathogenic from infection-induced antibodies. Clin Chem 53:1137–1143PubMedCrossRef
Metadata
Title
Detection of autoantibodies in a point-of-care rheumatology setting
Authors
Konstantin N. Konstantinov
Antonios Tzamaloukas
Robert L. Rubin
Publication date
01-08-2013
Publisher
Springer International Publishing
Published in
Autoimmunity Highlights / Issue 2/2013
Print ISSN: 2038-0305
Electronic ISSN: 2038-3274
DOI
https://doi.org/10.1007/s13317-013-0052-9
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits